MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

Onconova Therapeutics Inc

Gesloten

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+229.22% upside

Onconova Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 jan 2026, 21:55 UTC

Winsten

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 jan 2026, 23:52 UTC

Winsten

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 jan 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 jan 2026, 23:42 UTC

Marktinformatie

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 jan 2026, 23:40 UTC

Marktinformatie

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 jan 2026, 23:30 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 jan 2026, 23:30 UTC

Marktinformatie

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 jan 2026, 22:37 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 jan 2026, 21:59 UTC

Acquisities, Fusies, Overnames

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 jan 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

22 jan 2026, 21:44 UTC

Winsten

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 jan 2026, 21:32 UTC

Acquisities, Fusies, Overnames

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 jan 2026, 21:31 UTC

Acquisities, Fusies, Overnames

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 jan 2026, 21:31 UTC

Acquisities, Fusies, Overnames

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 jan 2026, 21:30 UTC

Winsten

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Capital One To Acquire Brex >COF

22 jan 2026, 21:13 UTC

Winsten

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 jan 2026, 21:11 UTC

Winsten

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 jan 2026, 21:11 UTC

Winsten

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 jan 2026, 21:10 UTC

Winsten

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 jan 2026, 21:06 UTC

Winsten

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 jan 2026, 21:05 UTC

Winsten

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 jan 2026, 21:05 UTC

Winsten

Capital One 4Q Rev $15.58B >COF

22 jan 2026, 21:05 UTC

Winsten

Capital One 4Q EPS $3.26 >COF

22 jan 2026, 21:05 UTC

Winsten

Capital One 4Q Net Interest Margin 8.26% >COF

22 jan 2026, 21:05 UTC

Winsten

Capital One 4Q Net $2.13B >COF

22 jan 2026, 21:05 UTC

Winsten

Capital One 4Q Adj EPS $3.86 >COF

22 jan 2026, 21:05 UTC

Winsten

Capital One 4Q Net Charge-Offs $3.8B >COF

22 jan 2026, 21:05 UTC

Winsten

Intuitive Surgical 4Q EPS $2.21 >ISRG

Peer Vergelijking

Prijswijziging

Onconova Therapeutics Inc Prognose

Koersdoel

By TipRanks

229.22% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8 USD  229.22%

Hoogste 8 USD

Laagste 8 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Onconova Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Financieel

$

help-icon Live chat